XstalBio Limited

XstalBio Ltd works collaboratively with international clients to help drive biopharmaceuticals and vaccines to market by enabling delivery of products to patients. We provide our experience, innovative technologies and expert consultancy to find efficient solutions to complex bioformulation challenges and accelerate the development of biologics. XstalBio has successfully formulated over 40 APIs working with many of the world’s top pharmaceutical and biotechnology companies as well as leading vaccine and animal health companies. APIs include mAbs, mAb fragments, cytokines, hormones, plasmids and peptides spanning a broad range of molecular weights and physical characteristics. In addition XstalBio has generated novel adjuvant formulations of many types of antigens including recombinant proteins, bacterial lysates, toxoids, polysaccharides and killed viruses. We routinely take-on challenging formulation issues and seek to solve these by applying innovative straightforward and scaled formulation technologies. We have an excellent track-record for meeting milestones and moving forward together with clients as their biopharmaceutical product challenges progress or change.